Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0149521 (chronic pancreatitis)
 7,199 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Seven patients were investigated 8--22 months after duodenectomy and pancreatectomy for chronic pancreatitis or cancer. Seven other patients, admitted for minor surgery, served as controls. 40 ml 100 mmol/l HCl was infused over 5 min into the jejunum 10 cm beyond the gastrojejunal stoma in the duodenectomized patients and 10 cm beyond the pylorus in the controls. Plasma immunoreactive secretin (IRS) increased from 3.0 +/- 0.8 pmol/l (mean +/- S.E.M.) to 9.8 +/- 0.5 pmol/l (p less than 0.01) in the duodenectomized patients. In the controls the increase was significantly higher than in the patients (p less than 0.01)--from 1.5 +/- 0.3 pmol/l to 19.5 +/- 3.3 pmol/l (p less than 0.01). The study shows that the jejunum is able to release IRS after acid infusion in duodenectomized patients.
 ...
PMID:Immunoreactive secretin release in patients after duodenectomy and partial or total pancreatectomy. 4 89

Altogether 25 patients with peptic ulcer and 26 patients with chronic pancreatitis were examined for gastric and pancreatic secretion. Histamine dihydrochloride (0.008-0.024 mg/kg) was employed to stimulate gastric secretion whereas cholecystokinin (2U/kg/h) and calcium gluconate (16 mg/kg) were used to stimulate pancreatic secretion. Lidocain (1.2 mg/kg), a blocker of Ca2+-channels, and lithium hydroxybutyrate (12 mg/kg), a blocker of phosphatidylinositol transformations, were employed for suppression of gastric and pancreatic secretion. The content of HCl, pepsinogen, fucose, cAMP and cGMP was measured in gastric juice, that of bicarbonates, amylase, lipase, trypsin, cAMP and cGMP in pancreatic juice. It has been shown that mechanisms dependent on cAMP and on extra- and intracellular Ca2+ are involved in the initiation and maintenance of gastric and pancreatic secretion. However, the contribution of those mechanisms is different as applied to the regulation of ions and enzymes, on the one hand, and to various enzymes, on the other.
 ...
PMID:[General mechanisms of regulation of the activity of the stomach and pancreas in peptic ulcer and chronic pancreatitis]. 272 25

We have designed a four lumen tube which has enabled us to aspirate duodenal juice while infusing endogenous stimuli into the lower part of duodenum. Exocrine pancreatic secretion and plasma immunoreactive secretin (IRS) levels have been simultaneously observed in response to intraduodenal infusion of 1-phenyl-1-hydroxy-n-pentane (PHP) and 0.1 N HCl in normal subjects, patients with diabetes mellitus and patients with chronic pancreatitis by use of this tube. (1) Pancreatic flow rate and bicarbonate concentration were found to increase to twice those of basal levels and plasma IRS levels rose significantly after infusion of PHP or HCl in normal subjects. The same tendency was observed in patients with diabetes mellitus. (2) Exocrine pancreatic secretion did not change after infusion of PHP or HCl in patients with chronic pancreatitis. Pancreatic flow rate, bicarbonate concentration and amylase output were significantly low in patients with diabetes mellitus. (3) Pancreatic flow rate and bicarbonate concentration incresed to about twice those of basal levels after both PHP and HCl infusion. On the other hand, although pancreatic amylase output increased significantly after infusion of HCl as compared with basal secretion, it did not change after infusion of PHP. It appeared reasonable to conclude that PHP is a morespecific substance for releasing secretin than HCl.
 ...
PMID:Plasma secretin level and exocrine pancreatic secretion in response to intraduodenal infusion of 1-phenyl-1-hydroxy-n-pentane and HCl by using a new four lumen tube. 746 2

In vitro testing of lipase survival of Panzytrat 25,000 homogenized in Tris HCl buffer and Lundh meal stimulated gastric or duodenal contents demonstrated favorable stability of lipase of this new preparation in the protein and fat containing gastric and duodenal juices of patients with chronic pancreatitis. Later an open, intra-individually controlled study with two doses of Panzytrat 25000 (5 x 1 and 5 x 2 capsules/day) was performed in 10 patients with severe pancreatic steatorrhoea. A diet containing 70 g of fat/day was offered and the 3-day fat loss of collected stools was measured in the last 3 days of 5-day equilibration periods with and without replacement therapy. After these short-term periods, patients were treated with 5 x 1 capsules of the drug for one month and body weight increases as well as patient's appraisals were registered. Stool weight and fat loss maximally decreased already in response to the 5-day treatment with 5 x 1 capsules of drug and double dose of the preparation did not further decrease steatorrhoea in most cases except 2 patient. Disappearance of fat loss was achieved in 3 out of ten patients. Body weight of patients increased in most cases and their subjective evaluation was also favorable.
 ...
PMID:[Treatment of pancreatic insufficiency with a preparation containing high lipase activity]. 915 36